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Abstract 
A simple and efficient protocol was developed for the synthesis of aryl azides directly 
from aryl carbinols using ZrCl4 as a Lewis acid catalyst. The azides were converted to 
novel triazoles under click reaction conditions and evaluated the resulting triazoles for 
their antimicrobial activity against various strains. 
 
 
KEYWORDS: Zirconium(IV) chloride, Click chemistry, 1,2,3-Triazole, antimicrobial 
activity 
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Alcohol functionality, which is an attractive source of electrophile in view of green 
chemistry principles,[1a] is not a good leaving group. Hence, the derivatization becomes 
essential for its facile displacement.[1b] Though, several methods were reported[2–4]  for the 
direct nucleophilic substitution of alcohols, many of them suffer from elevated 
temperatures, longer reaction times, or stoichiometric use of the reagents. Thus, the 
development of newer methods for direct conversion of a C-OH bond into a C-N bond,  
gains importance, since the amine group is very common in many natural products as 
well as pharmaceutically important compounds.[5] Thus, the direct displacement of an 
alcohol group with an azide group gains prominence, since the azide group is a direct 
source of amines, in addition to its stability and reactivity in click chemistry[6] and 
bioconjugation.[7] The most common method for the synthesis of azide is by the 
Mitsunobu displacement[8] with HN3 and its modifications.[9] The other C-N bond 
formation methods include, a two step conversion of alcohol to azide through 
mesylate,[10a] palladium catalyzed hydroazidation of homoallyl alcohols[10b] and  gold 
catalyzed direct amination of benzhydryl alcohols.[10c] In continuation of our interest on 
the catalytic applications of ZrCl4 as a Lewis acid for various organic transformations,[11] 
we herein, disclose ZrCl4 catalyzed conversion of the known carbinols 1-5[12] (Scheme 1), 
into the corresponding azides 6-10, with TMSN3 in CH3CN at room temperature, click 
reaction of azides and biological evaluation of the derived 1,2,3-triazoles (6a -10d).  
 
RESULTS AND DISCUSSION 
Accordingly, carbinol 1 on reaction with TMSN3 in the presence of ZrCl4 (5 mol%)  in 
anhydrous CH2Cl2 (Scheme 2) gave 6 in 38% yield. Further, reaction of 1 in toluene or 
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1,4-dioxane afforded azide 6 in lower yields along with the respective TMS ether in 1a in 
higher yields. However, reaction of 1 in acetonitrile or nitromethane was found to be 
good and gave 6 in excellent yields, with no traces of 1a. Further, reaction of 1 in CH3CN 
with different mol% of ZrCl4 (10, 15, 20) revealed 10 mol% is the optimum quantity. 
 
A comparative study on the conversion of carbinol 1 to azide 6 was made using NaN3 in 
the presence of ZrCl4 (10 mol%) in different solvents. The results, as tabulated in the 
Scheme 2, evidently indicate that TMSN3 is superior in the conversion of carbinol to 
azide. 
 
Having established the reaction conditions, reaction of 1-5 in CH3CN with ZrCl4 (10 
mol%) at room temperature for 0.5 h afforded the respective azides 6 (90%), 7 (89%), 8 
(90%), 9 (87%) and 10 (82%) respectively (Scheme1). 
 
Antimicrobial Activity Of Azides: 
Azides are energy rich molecules with many applications,[13] and are known for biocidal 
property. The synthesized azides 6-10 were evaluated for antibacterial activity by agar 
well plate method against four bacterial cultures, viz Escherichia coli, Klebsiella 
pneumoniae, Bacillus subtilis and Micrococcus luteus and compared with the 
antibacterial activity of streptomycin sulphate (Himedia) at 37 °C for 24 h. The data 
revealed that azides 7 and 8 were active against all the test cultures (Table 1), while the 
remaining azides 6, 9 and 10 have showed no activity. Analysis of the inhibition zone 
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data for 7 and 8 revealed that antibiotic activity is 50-55%, suggesting them to be only 
less potent with reference to streptomycin sulfate.  
 
The antibacterial activity was evaluated by measuring the inhibition zone formed around 
the wells at a concentration of 100 µg. Wells containing sterile water and solvent 
(DMSO) were used as controls. 
 
Having found two of the five azides with antibacterial activity, it was proposed to convert 
them in to 1,2,3-triazoles and evaluate their antibacterial activity. 1,2,3-Triazoles, 
prepared by Huisgen 1,3-dipolar cycloaddition reaction[14] and their wide range of 
biological applications in research, made them very attractive targets.  Click chemistry 
reaction conditions, using Cu(I) as a catalyst were adopted in the present study to obtain 
the 1,4-regioisomers[15] of triazoles. 
 
Accordingly, azide 6 was treated with phenyl acetylene 11a in the presence of sodium 
ascorbate and CuSO4.5H2O in t-BuOH-H2O at room temperature for 8 h to give 6a in 
95% yield. Having established the reaction conditions for the conversion of azide to 
1,2,3-triazole to create diverse triazoles, each of the five azides 6-10 were independently 
treated with four acetylenes, viz 11a-d to afford the triazoles 6a-d to 10a-d respectively. 
All the triazoles were charcterised by spectral and analytical methods. 
 
Antimicrobial Activity Of Triazoles 
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Triazoles, since are known to be powerful antimicrobial agents,[16] the synthetic triazoles 
were evaluated for their antibacterial behaviour (Table 2) against gram -ve (E. coli and K. 
pneumoniae) and gram +ve (B. subtilis and M. luteus) microbial strains, by adopting the 
same  methodology used for the azides.  
 
All the synthetic triazoles showed significant antibacterial activity against the tested 
cultures. Maximum activity was indicated for triazole 9b against B. subtilis (25 mm) and 
M. luteus (24 mm), whereas, minimum activity was indicated for observed for triazole 
8d. SAR (structure activity relationship) studies revealed that the parent azide moieties 
(phenyl, methyl and isobutyl) having no activity, also have exhibited good antibacterial 
activity when they were converted into triazoles (6a-d, 9a-d and 10-d). Further 
observations revealed that among the triazoles, compounds with NHBoc and n-hexyl side 
chains (6b, 6d, 9b, 9d, 10b and 10d) showed good intensity of antibacterial activity 
compared with the other two side chains (phenyl and -CH2OH). SAR studies on 7a-d and 
8a-d prepared from active azide moieties 7 and 8 inferred an increase in the antibacterial 
activity of 7c and 7d, while, triazoles from 8 displayed diminished activity.  
 
MIC By Tube Dilution Method 
Out of the several synthetic triazoles, ten triazoles (Table 3) were selected for MIC 
(minimum inhibitory concentration) studies. From the studies, it is evident that triazole 
9b showed MIC of 15.625 µg/mL concentration to inhibit the growth of the organism 
against B. subtilis and K. pneumoniae. All the new triazoles showed moderate MIC 
values with a concentration of 31.25 and 62.5 µg/mL. Further, it was also observed that 
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the synthetic triazoles showed lesser MIC values than the standard (streptomycin) against 
P. putida.  
 
Experimental Section: 
General Experimental Details 
Solvents were dried over standard drying agents and freshly distilled prior to use. All 
commercially available chemicals were used without further purification. All reactions 
were performed under Nitrogen. 1H NMR and 13C NMR spectra were measured with 
Varian Gemini FT 200 MHz spectrometer, Bruker Avance 300 MHz, Unity 400 MHz 
and Inova 500 MHz with tetramethylsilane as internal standard for solutions in CDCl3. J 
values are given in Hz. Chemical shifts were reported in ppm relative to solvent signal. 
All column chromatographic separations were performed using silica gel (Acme’s, 60-
120 mesh). Organic solutions were dried over anhydrous Na2SO4 and concentrated below 
40 ºC in vacuo. IR-spectra were recorded on FT IR (Perkin-Elmer IR-683) 
spectrophotometer with NaCl optics. JASCO DIP 300 digital polarimeter was used for 
measurement of optical rotations at 25 °C. Mass spectra were recorded on direct inlet 
system or LC by MSD trap SL (Agilent Technologies), the HRMS data were obtained 
using Q-TOF mass spectrometry. 
 
1-(Azido(Phenyl)Methyl)-4-Methoxybenzene (6):  
A stirred solution of alcohol 1 (2.0 g, 9.35 mmol) in acetonitrile (10 mL) at 0 °C was 
sequentially treated with azidotrimethylsilane (3.0 mL, 23.38 mmol) and ZrCl4 (0.22 g, 
0.93 mmol) and stirred for 30 min. The reaction mixture was diluted with water (10 mL) 
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and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with 
brine (10 mL) and dried (Na2SO4). Solvent was evaporated and the residue purified by 
column chromatography (60-120 mesh Silica gel, 3% EtOAc in pet. ether) to afford 6 
(2.02 g, 90%) as a yellow liquid; IR (CHCl3): 3030, 2091, 1609, 1510, 1243, 1174, 1031 
cm-1; 1H NMR (300 MHz, CDCl3): δ 7.37-733 (m, 2H, ArH), 7.32 (m, 3H, ArH), 7.21 (d, 
2H, J = 8.7 Hz, ArH), 6.88 (dt, 2H, J = 2.1, 8.8 Hz, ArH), 5.67 (s, 1H, ArCH), 3.97 (s, 
3H, OMe); 13C NMR (75 MHz, CDCl3): δ 159.2, 139.7, 131.6, 128.6, 128.5, 127.8, 
127.1, 113.9, 67.9, 55.1.  
 
1-((4-Methoxyphenyl)(Phenyl)Methyl)-4-Phenyl-1H-1,2,3-Triazole (6a):  
A solution of azide 6 (0.20 g, 0.84 mmol) and phenyl acetylene 11a (0.09 mL, 0.84 
mmol) in t-BuOH (1 mL) and water (1 mL) was treated with sodium-ascorbate (0.01 g, 
0.04 mmol) followed by CuSO4.5H2O (0.02 g, 0.08 mmol) at room temperature and 
stirred for 8 h. Solvent was evaporated from the reaction mixture, residue diluted with 
water (5 mL) and extracted with EtOAc (2 x 10 mL). Combined organic layer were 
washed with brine (5 mL) and dried (Na2SO4). Solvent was evaporated and purified the 
residue by column chromatography (60-120 mesh Silica gel, 15% EtOAc in pet. ether) to 
afford 6a (0.27 g, 95%) as a white solid; mp 157-159 oC; IR (CHCl3): 3032, 2928, 1609, 
1512, 1456, 1250, 1178, 1030, 763, 739 cm-1; 1H NMR (500 MHz, CDCl3): δ 7.81 (d, 
2H,  J = 7.2 Hz, ArH), 7.60 (s, 1H, CH), 7.45-7.21 (m, 6H, ArH), 7.17-7.07 (m, 5H, ArH, 
ArCH), 6.91 (d, 2H, J = 8.7 Hz, ArH), 3.82 (s, 3H, OMe); 13C NMR (75 MHz, CDCl3): δ 
129.6, 128.8, 128.7, 128.4, 128.1, 127.7, 125.6, 119.5, 114.3, 67.6, 55.3; HRMS (ESI+) 
m/z calcd for C22H20N3O (M+ + H) 342.16009, found 342.16022. 
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Experimental Procedure For MIC Studies: 
All the test strains (E. coli, B. subtilis, K. pneumonia, M. luteus and P.putida), each 1 mL 
volume (OD equal to match the turbidity of a Mac Farland 0.5 standard tube) were 
inoculated in nutrient (1 mL) broth with final compound concentrations of 250 µg/mL to 
0 µg/mL and standard drug (Streptomycin) concentration from 400 µg/mL to 6.25 
µg/mL. All the tubes were incubated at 37 oC for 12-16 h. The turbidity of each tube is 
measured with respect to control tube. MIC values are defined as the lowest 
concentration of compound at which growth is completely inhibited for at least for 8 h. 
 
SUPPORTING INFORMATION 
Full experimental details, spectral data of the products, 1H NMR, 13C NMR and HRMS 
spectra of all the new compounds can be accessed on the publisher’s website. 
 
CONCLUSION 
In conclusion, an efficient method for the conversion of C-O bond (carbinols) to C-N 
bond (to azide), catalyzed by ZrCl4 has been developed. The method reported is not only 
simple to operate, but also affords the product azides in short duration of time in high 
yields. The azides were converted into 1,2,3-triazoles by click chemistry. The azides and 
derived triazoles were evaluated for their antimicrobial activity against gram +ve and -ve 
bacteria. The study revealed some of the triazoles with interesting antibacterial activity. 
Further SAR studies to derive better compounds with better activity are in progress. 
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Table 1 Antimicrobial activity of azides  
Entry Aryl azides R1 E. 
coli 
M. 
luteus 
K. 
pneumoniae 
B. 
subtilis 
1 6 Phenyl 00 00 00 00 
2 7 Isovanillyl 14 16 16 15 
3 8 Napthyl 15 17 15 14 
4 9 Methyl 00 00 00 00 
5 10 Isobutyl 00 00 00 00 
 Control (DMSO)  00 00 00 00 
 Streptomycin 
sulfate 
 32 31 30 33 
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Table 2 Antimicrobial activity of triazole derivatives 
Entry Triazoles R1 R2 E. 
coli 
M. 
luteus 
K. 
pneumoniae 
B. 
subtilis 
1 6a Phenyl Phenyl 12 12 12 15 
2 6b Phenyl n-hexyl 13 15 16 15 
3 6c Phenyl CH2OH 13 16 12 11 
4 6d Phenyl CH2NHBoc 18 18 16 15 
5 7a Isovanillyl Phenyl 20 11 15 16 
6 7b Isovanillyl n-hexyl 17 0 16 14 
7 7c Isovanillyl CH2OH 20 20 20 20 
8 7d Isovanillyl CH2NHBoc 20 15 22 22 
9 8a Napthyl Phenyl 0 0 17 17 
10 8b Napthyl n-hexyl 11 14 12 0 
11 8c Napthyl CH2OH 17 15 17 14 
12 8d Napthyl CH2NHBoc 0 10 0 0 
13 9a Methyl Phenyl 14 24 16 15 
14 9b Methyl n-hexyl 15 24 21 25 
15 9c Methyl CH2OH 12 15 12 12 
16 9d Methyl CH2NHBoc 12 19 13 16 
17 10a Isobutyl Phenyl 11 15 11 17 
18 10b Isobutyl n-hexyl 12 17 15 16 
19 10c Isobutyl CH2OH 12 11 12 13 
20 10d Isobutyl CH2NHBoc 13 18 16 18 
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 Control   0 0 0 0 
 standard   32 31 30 33 
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Table 3 MIC studies 
Entry Compound E. coli B. subtilis K. pneumoniae M. luteus P. putida 
1 6b 31.25 31.25 31.25 31.25 31.25 
2 6d 31.25 31.25 31.25 62.5 62.5 
3 7a 31.25 62.5 31.25 31.25 >125 
4    7c 15.625 62.5 62.5 31.25 62.5 
5 7d 31.25 62.5 62.5 62.5 62.5 
6 8c 62.5 31.25 31.25 31.25 62.5 
   7 9a 31.25 62.5 62.5 31.25 62.5 
    8 9b >125 15.625 15.625 >125 >125 
9 9d 62.5 62.5 62.5 62.5 62.5 
10 10d 31.25 62.5 62.5 62.5 125 
 Streptomycin 6.25 6.25 6.25 6.25 150 
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Scheme 1 
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Scheme 2 
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Scheme 3 
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